𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Therapeutic targets in chronic myeloid leukaemia

✍ Scribed by Nicholas B. Heaney; Tessa L. Holyoake

Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
162 KB
Volume
25
Category
Article
ISSN
0278-0232

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Chronic myeloid leukaemia (CML) is a clonal disorder of the haemopoietic stem cell arising as a consequence of the formation of the bcr‐abl oncogene. The particular molecular basis of this condition has enabled the development of therapies that selectively target diseased cells. The success of the rationally designed first‐line therapy imatinib mesylate (IM) is tempered by the problems of disease persistence and resistance. Novel strategies have been identified to take forward therapy in CML and these will be discussed in this review. This work is generated from a review of published literature and contains particular insight into the work performed by our group in this field. Copyright Β© 2007 John Wiley & Sons, Ltd.

πŸ“œ SIMILAR VOLUMES

Telomeres and telomerase in chronic myel
Telomeres and telomerase in chronic myeloid leukaemia: impact for pathogenesis, disease progression and targeted therapy
✍ Gunhild Keller; Ute Brassat; Melanie Braig; Denise Heim; Henning Wege; Tim H. Br πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 242 KB

## Abstract Telomeres are specialized structures localized at the end of human chromosomes. Due to the end replication problem, each cell division results in a loss of telomeric repeats in normal somatic cells. In germ line and stem cells, the multicomponent enzyme telomerase maintains the length o